AIM: To investigate in vitro and in vivo therapeutic effects of histone deacetylase inhibitors NVP-LAQ824 and NVP-LBH589 on biliary tract cancer. METHODS: Cell growth inhibition by NVP-LAQ824 and NVP-LBH589 was studied in vitro in 7 human biliary tract cancer cell lines by MTT assay. In addition, the anti-tumoral effect of NVP-LBH589 was studied in a chimeric mouse model. Anti-tumoral drug mechanism was assessed by immunoblotting for acH4 and p21( WAF-1/CIP-1), PARP assay, cell cycle analysis, TUNEL assay, and immunhistochemistry for MIB-1. RESULTS: In vitro treatment with both compounds significantly suppressed the growth of all cancer cell lines [mean IC(50) (3 d) 0.11 and 0.05 micromol/L, respectively], and was associated with hyperacetylation of nucleosomal histone H4, increased expression of p21( WAF-1/CIP-1), induction of apoptosis (PARP cleavage), and cell cycle arrest at G2/M checkpoint. After 28 d, NVP-LBH589 significantly reduced tumor mass by 66% (bile duct cancer) and 87% (gallbladder cancer) in vivo in comparison to placebo, and potentiated the efficacy of gemcitabine. Further analysis of the tumor specimens revealed increased apoptosis by TUNEL assay and reduced cell proliferation (MIB-1). CONCLUSION: Our findings suggest that NVP-LBH589 and NVP-LAQ824 are active against human biliary tract cancer in vitro. In addition, NVP-LBH589 demonstrated significant in vivo activity and potentiated the efficacy of gemcitabine. Therefore, further clinical evaluation of this new drug for the treatment of biliary tract cancer is recommended.
AIM: To investigate in vitro and in vivo therapeutic effects of histone deacetylase inhibitors NVP-LAQ824 and NVP-LBH589 on biliary tract cancer. METHODS: Cell growth inhibition by NVP-LAQ824 and NVP-LBH589 was studied in vitro in 7 humanbiliary tract cancer cell lines by MTT assay. In addition, the anti-tumoral effect of NVP-LBH589 was studied in a chimeric mouse model. Anti-tumoral drug mechanism was assessed by immunoblotting for acH4 and p21( WAF-1/CIP-1), PARP assay, cell cycle analysis, TUNEL assay, and immunhistochemistry for MIB-1. RESULTS: In vitro treatment with both compounds significantly suppressed the growth of all cancer cell lines [mean IC(50) (3 d) 0.11 and 0.05 micromol/L, respectively], and was associated with hyperacetylation of nucleosomal histone H4, increased expression of p21( WAF-1/CIP-1), induction of apoptosis (PARP cleavage), and cell cycle arrest at G2/M checkpoint. After 28 d, NVP-LBH589 significantly reduced tumor mass by 66% (bile duct cancer) and 87% (gallbladder cancer) in vivo in comparison to placebo, and potentiated the efficacy of gemcitabine. Further analysis of the tumor specimens revealed increased apoptosis by TUNEL assay and reduced cell proliferation (MIB-1). CONCLUSION: Our findings suggest that NVP-LBH589 and NVP-LAQ824 are active against humanbiliary tract cancer in vitro. In addition, NVP-LBH589 demonstrated significant in vivo activity and potentiated the efficacy of gemcitabine. Therefore, further clinical evaluation of this new drug for the treatment of biliary tract cancer is recommended.
Authors: S Saijyo; T Kudo; M Suzuki; Y Katayose; M Shinoda; T Muto; K Fukuhara; T Suzuki; S Matsuno Journal: Tohoku J Exp Med Date: 1995-09 Impact factor: 1.848
Authors: Helmut Witzigmann; Frieder Berr; Ulrike Ringel; Karel Caca; Dirk Uhlmann; Konrad Schoppmeyer; Andrea Tannapfel; Christian Wittekind; Joachim Mossner; Johann Hauss; Marcus Wiedmann Journal: Ann Surg Date: 2006-08 Impact factor: 12.969
Authors: Patricia Maiso; Xonia Carvajal-Vergara; Enrique M Ocio; Ricardo López-Pérez; Gema Mateo; Norma Gutiérrez; Peter Atadja; Atanasio Pandiella; Jesús F San Miguel Journal: Cancer Res Date: 2006-06-01 Impact factor: 12.701
Authors: A Knuth; H Gabbert; W Dippold; O Klein; W Sachsse; D Bitter-Suermann; W Prellwitz; K H Meyer zum Büschenfelde Journal: J Hepatol Date: 1985 Impact factor: 25.083
Authors: Y Shimizu; A J Demetris; S M Gollin; P D Storto; H M Bedford; S Altarac; S Iwatsuki; R B Herberman; T L Whiteside Journal: Int J Cancer Date: 1992-09-09 Impact factor: 7.396
Authors: James L Chen; Tanios Bekaii-Saab; Daniel H Ahn; Milind Javle; Chul W Ahn; Apurva Jain; Sameh Mikhail; Anne M Noonan; Kristen Ciombor; Christina Wu; Rachna T Shroff Journal: Cancer Date: 2016-08-06 Impact factor: 6.860
Authors: Chao Yang; Ming Xu; Huo-Jian Shen; Hong-Yi Zhu; Fu Li; Min He; Tao Chen; Jian Wang; Wei-Jin Shi; Fu Ji Journal: Int J Clin Exp Pathol Date: 2014-01-15
Authors: Martin Haefner; Thilo Bluethner; Manuel Niederhagen; Christian Moebius; Christian Wittekind; Joachim Mossner; Karel Caca; Marcus Wiedmann Journal: World J Gastroenterol Date: 2008-06-21 Impact factor: 5.742
Authors: Joana N R Dias; Sandra I Aguiar; Diane M Pereira; Ana S André; Lurdes Gano; João D G Correia; Belmira Carrapiço; Barbara Rütgen; Rui Malhó; Conceição Peleteiro; João Goncalves; Cecília M P Rodrigues; Solange Gil; Luís Tavares; Frederico Aires-da-Silva Journal: Oncotarget Date: 2018-06-19
Authors: Morgan J Homan; Andrea Franson; Karthik Ravi; Holly Roberts; Manjunath P Pai; Cai Liu; Miao He; Aleksas Matvekas; Carl Koschmann; Bernard L Marini Journal: Cancer Chemother Pharmacol Date: 2021-06-11 Impact factor: 3.333